Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Opus Genetics: Clinical Trials & FDA Approval Profile

Opus Genetics (Global / Institutional) sponsors 15 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 4 active protocols (4 recruiting now), 11 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)150 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Opus Genetics
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)15
Active Pipeline (Recruiting Now)4 (4)
Completed vs Stopped Early11 / 0 (0.0%)
Median Closed Actual Enrollment150 participants
Physical Hospital Site Disclosure60.4% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Opus Genetics
Hospital Research SiteLocationShared Protocols
University of Pennsylvania Abramson Cancer CenterPhiladelphia, PA2
Eye Research FoundationNewport Beach, CA2

Explore interactive annual charts and M&A subsidiary rollups in the Opus Genetics Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI